menu toggle
Microsoft outage update
We are seeing encouraging recovery progress as Microsoft continues to restore services following yesterday’s global disruption. Email service is continuing to improve, and we continue to closely monitor the situation until full recovery is confirmed. For any urgent needs, we recommend calling Customer Service directly for support. Thank you for your patience and understanding as we work through this outage.

October 1, 2026

Now available CLIGAVYX™

CLIGAVYX™ (fulvestrant) injection, for intramuscular use, is an estrogen receptor antagonist indicated for the treatment of:
 
  • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
  • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
  • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.
  •  HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.


Please see full prescribing information here.

We are NABP accredited